Waldenström's macroglobulinaemia (Q34774268)

4 August 2017

1 reference

title

Waldenström's macroglobulinaemia. (English)

1 reference

4 August 2017

Johnson SA

1

1 reference

4 August 2017

Oscier DG

series ordinal

2

1 reference

4 August 2017

Leblond V

series ordinal

3

1 reference

4 August 2017

publication date

1 September 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

16

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

175-184

1 reference

Waldenström macroglobulinemia caused by extranodal marginal zone B-cell lymphoma: a report of six cases

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Clinicopathological correlates of IgM paraproteinemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

The spectrum of IgM monoclonal gammopathy in 430 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Therapeutic plasma exchange: an update from the Canadian Apheresis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Waldenström's macroglobulinemia: long-term results with the M-2 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Fludarabine therapy in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Fludarabine treatment in resistant Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Cladribine for Waldenström's macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Treatment of Waldenstrom's macroglobulinemia with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Treatment of resistant Waldenstrom's macroglobulinemia with high dose glucocorticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2802%2900016-4

7 January 2021

10.1016/S0268-960X(02)00016-4

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kmypnjpukzhtvppxbzqhj2riwe

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_kmypnjpukzhtvppxbzqhj2riwe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kmypnjpukzhtvppxbzqhj2riwe

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/kmypnjpukzhtvppxbzqhj2riwe

1 reference

30 July 2022